Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03502746 · FLOW

Participant flow

Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma · Source last updated 2024-05-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Nivolumab 240mg IV + Ramucirumab 8mg/kg IV Nivolumab: Nivolumab 240mg, IV over 30 minutes. Ramucirumab: 8mg/kg, IV over 60 minutes.
    id
    FG000
    title
    Nivolumab + Ramucirumab
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        34
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        34
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Nivolumab 240mg IV + Ramucirumab 8mg/kg IV Nivolumab: Nivolumab 240mg, IV over 30 minutes. Ramucirumab: 8mg/kg, IV over 60 minutes.
    id
    FG000
    title
    Nivolumab + Ramucirumab
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        34
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        34
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice